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A B S T R A C T
Behçet disease is a recurrent systemic vasculitis of unknown etiology, that involves vessels of nearly all
sizes and types. Because of this, disease manifestations can occur at many sites throughout the body.
Central nervous system (CNS) involvement may be parenchymal or nonparenchymal and has a global
prevalence that ranges from 3% to 10%. Main signs of CNS involvement are pyramidal and those resul-
ting from brain stem lesions. Aseptic meningitis, mental changes, sphincter disturbances, pseudobulbar
syndrome, and deep sensory abnormalities may be seen. Analysis of cerebrospinal fluid, computed
tomography (CT), magnetic resonance imaging (MRI), single-photon emission computed tomography
(SPECT) and brain angiography offer assistance in the diagnosis. The course of disease can be primary
progressive, secondary progressive or have a relapsing-remitting profile.
Boluses of methylprednisolone for three days followed by cyclophosphamide are the treatment of choice.
This papers discusses these aspects of neuro-Behcet on the basis of complex clinical case.
Key-words: Behcet`s disease; Neuro-Behçet.
R E S U M O
A Doença de Behcet consiste numa vasculite sistémica recorrente de etiologia desconhecida que envolve
vasos de quase todos os tamanhos e tipos. Por este motivo, as manifestações da doença podem afectar
múltiplos órgãos e sistemas. O envolvimento do sistema nervoso central pode ser parenquimatoso ou
não-parenquimatoso e tem uma prevalência de 3 a 10%. Os principais sintomas são de tipo piramidal e
ainda os que resultam do atingimento do tronco cerebral. Meningite asséptica, alterações mentais, dis-
túrbios dos enfincteres, síndrome pseudo-bulbar e anormalidades sensoriais profundas podem também
ocorrer. A análise do líquido cefalo-raquídeo, ressonância magnética nuclear, o SPECT (single-photon
emission computed tomography) e a angiografia cerebral são instrumentos úteis no diagnóstico. O curso
da doença pode ser progressivo (primário e secundário) ou assumir um padrão com remissões e agrava-
mentos.
Bólus de metilprednisolona por 3 dias, seguidos de ciclofosfamida constituem, actualmente, o trata-
mento de escolha.
Este trabalho aborda estes e outros problemas de Neuro-Behcet, tomando como base a discussão de um
caso clínico complexo.
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Introduction
Behcet’s disease, first described in 1937 by Hulusi
Behcet, a Turkish dermatologist, is a multisys-
temic vasculitis, of unknown etiology, which
involves blood vessels of different types and sizes,
with a recurrent course. Prevalence is higher in
Mediterranean countries, the Middle East and
Eastern Asia, particularly Japan (along the ancient
«silk road»). Males are more frequently affected.
The mean age of onset ranges from 20-35 years,
although cases have been described with an onset
from 1 to 80 years of age1,2,3. The role of the HLA
B51 in this disease has been extensively studied in
the last few years, and it has been reported that
the allele HLA-B5101 was found in 72% of the
patients in which it seems to predispose to a more
severe prognosis, particularly in males4. Despite
the predisposition to Behçet`s disease conferred
by HLA-B51, familial cases are not the role, con-
sisting only about 5% of cases. Studies by Yazici et
al5 show that an earlier onset is associated with a
worse prognosis. Males develop severe ocular di-
sease more frequently whereas females present
more commonly with erythema nodosum. 
The International Study Group Criteria (ISG
criteria) for Behcet’s Disease, are presented in Ta-
ble 16. They have a sensitivity of 91% and a specifi-
city of 96%7.
– Oral ulcerations are usually painful, of varia-
ble size, affecting the lips, tongue, gingiva and
cheeks. They usually heal after 2 to 10 days, wi-
thout scarring, but are typically recurrent.
– Genital ulcerations are more specific of the
condition and leave a scar upon healing.
– Ocular involvement represents one of the
most serious manifestations as it is frequently as-
sociated with severe sequelae including blind-
ness. Ophthalmologic manifestations include
acute iridocyclitis, cataracts, glaucoma and poste-
rior segment involvement with retinal vasculitis,
vitritis, panuveitis, retinal edema and retinal
detachment, arterial and venous occlusion and
cytoid macular degeneration.
Ocular involvement is bilateral in about 80% of
the cases and occurs more frequently in males. It
is usually associated with disease flares but sel-
domly occurs as presenting feature.
– Regarding cutaneous manifestations, the
most frequent ones are papulopustular lesions,
and erythema nadosum like lesions, superficial
thrombphlebitis (usually clinically difficult to tell
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Table 1. International Study Group Criteria for
Behçet´s Disease1,2,6.
1. Recurrent oral ulceration: minor aphthous, ma-
jor aphthous, or herpetiform ulceration observed by
physician or patient, wich recurred at least 3 times in
one 12-month period
Plus 2 of:
2. Recurrent genital ulceration: aphthous ulcera-
tion or scaring, observed by physician or patient
3. Eye lesions: anterior uveitis, posterior uveitis, or
cells in vitreous on slit-lamp examination; or retinal vas-
culitis observed by an ophthalmologist
4. Skin lesions: erythema nodosum observed by
physician or patient, pseudofolliculitis, or papulopus-
tular lesions; or acneiform nodules observed by physi-
cian in postadolescent patients not on corticosteroid
therapy.
5. Positive pathergy test: read by physician at 
24-48 hr
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from erythema nodosum like lesions) as well as
macular eruptions and dermographism. Less fre-
quently, purpura, bullae and digital necrotizing
vasculitis can be observed.
– The pathergy test elicits a nonspecific cuta-
neous hyperreactivity: a sterile 20 gauge needle is
inserted to 1cm depth in the anterior surface of
the forearm, then is revolved and taken back. The
procedure can be repeated at three different sites
and the result is read at 24 to 48 hours: the test is
considered positive if an aseptic papule or pus-
tule has been produced1,2. Yazici et al. proposed
the utilization of a solution of monosodium urate
to precipitate the pathergy reaction (2,8).
The result of this test depends on the popula-
tion studied and the size of the needle. Only 40 to
50% of Behcet’s patients will present with a posi-
tive pathergy test. False positives can be observed
in seronegative spondylarthropaties and in
chronic myelogenous leukemia after IFN a treat-
ment1.
– Arthralgia and arthritis affect preferentially
large joints of lower extremities, but any joint can
be involved including the sacroiliac. The pattern
is usually subacute, intermittent and not defor-
ming. Erosions are rarely seen, but radiological
evidence of bone proliferation is relatively com-
mon at tendon and ligament insertions. 
– Vascular inflammation is commonly heral-
ded by venous and arterial thrombosis. A recent
review of the literature by Bartlett et al2,9 shows
that venous manifestations occur in about 33% of
the patients. Arterial aneurysms are seen in about
7% of the cases. The abdominal aorta is the most
common site of arterial inflammation, followed
by the femoral and pulmonary arteries. 
– Gastrointestinal symptoms are present in up
to 50% of the patients. They include diarrhea,
abdominal pain, and hemorrhage. The most fre-
quent lesions are ulcers, affecting any section of
the GI tract. They are frequently large and deep
with a considerable tendency to perforation1,2,10.
Differential diagnosis with inflammatory bowel
diseases is mandatory.
– Lung manifestations are mainly due to vas-
culitis, leading to thrombosis or aneurysm forma-
tion. Multiple pulmonary aneurysms can cause
massive hemoptysis, a medical emergency, that
can be fatal in 40 to 80% of the cases. Hemoptysis,
recurrent dry cough, fever, dyspnea and pleuritic
chest pain, are the cardinal signs of pulmonary
involvement. Radiological findings include pleu-
ral effusions, diffuse infiltrates and nodular opa-
cities1,2,10,11.
– Heart involvement may consist of granulo-
matous endocarditis, recurring ventricular arrhy-
thmias. myocarditis and pericarditis, valvular re-
gurgitation and coronary arteritis. The heart is
affected in 5 to 10% of the patients1,11-14.
– Less common manifestations includes epi-
didymitis, (with a prevalence of 4 to 11%, in dif-
ferent series), acute glomerulonephritis, IgA
nephropathy, renal vein thrombosis, and secon-
dary amiloidosis, described in 2% of the patients.
Sometimes lymph nodules enlargement can be
the presenting sign, suggesting lymphoprolifera-
tive disease1,2,10.
Neurologic involvement: Neuro-Bechet’s.
Central nervous system (CNS) involvement has a
prevalence that ranges from 3 to 10%, and repre-
sent the first manifestation of the disease in about
5% of the patients. Males are more commonly
affected than females1,2, and typically have more
severe manifestations15. CNS disease is associated
with considerable mortality2.
Symptoms have a subacute onset in about 50%
of the cases.
Pyramidal signs are the most common4; they
usually cause spastic paralysis or paresia, Babins-
ki sign, clonus and speech disturbance. Other
clinical manifestations consist of cranial nerves
paresis (paresis of the III and VI cranial nerves is
not uncommon), aseptic meningitis, cerebellar
and sensory signs and symptoms, headaches,
increased intracranial pressure and focal motor
deficits, that may progress to hemi or parapare-
sia. Peripheral neuropathy and isolated cerebellar
involvement are distinctly rare in Behçet’s15. So-
me authors refer that up to 30% of these patients
present psychiatric manifestations including
confusion, hallucinations and agitation1. 
A recent review of 200 patients (155 men, 45
women) with CNS involvement found that paren-
chymal involvement was more frequent than
nonparenchymal (19%). 51% of the patients wi-
thin parenchymal involvement group had brain-
stem involvement, 19% isolated pyramidal signs,
15% hemispheric involvement, and 14% spinal
cord involvement16,17.
Poor prognosis was found in patients with pa-
renchymal involvement, especially brainstem in-
volvement, in those with abnormal cerebrospinal
fluid (CSF) analysis (elevated protein levels,
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and/or pleocytosis), and in those who have two
or more attacks, who were dependent at admit-
tance, who relapse during steroid tapering and in
those who have a progressive course (primary or
secondary).
In another series of 50 patients18 adverse prog-
nostic factors include: young age of onset, brains-
tem involvement, high frequency of relapses and
the presence of CSF abnormalities.
As it was referred before in Behçet`s disease
there is a systemic vasculopathy and a tendency
to venous thrombus formation. Increased levels
of factor VIII-related antigen are found in patients
with major vessel involvement. It has been also
described defects in prostacyclin production in
the vessel wall, antiendothelial cell antibodies
and increased endothelin levels in serum3.
Despite this knowledge the pathogenesis of
CNS involvement in Behcet’s disease is still not
clear; according to some authors, ischemia se-
condary to vasculitis, especially venulitis has a
primordial role, whereas others underline the
importance of autoimmune demyelization (2).
According to Powell et al. a non-specific inflam-
matory reaction with mononuclear and/or neu-
trophilic predominance seems to occur in com-
mon19. The earliest lesions in the CNS may in-
volve a perivascular infiltration of lymphocytes
and histiocytes followed by a perivascular fibrosis
and nerve fiber degeneration3.
In postmortem examination of the brain, de-
myelization is the most common finding, follo-
wed by multifocal encephalomalacia accompa-
nied by perivascular cell infiltration. Other le-
sions include meningoencephalitis, cerebral
atrophy, and vascular thrombosis1,20. 
Computed tomography (CT), magnetic reso-
nance imaging (MRI), single photon emission
computed tomography (SPECT), and brain an-
giography are indicated to help in the diagnosis of
CNS involvement. Analysis of cerebrospinal fluid
usually shows pleocytosis, with a predominance
of PMN cells in the acute phase, and lymphocytes
after a few days, elevated protein content and
occasionally low glucose3. Intrathecal synthesis of
immunoglobulin is not or very rarely seen.
CT scans and MRI images may show anatomic
correlates; CT scan show hypodense areas and
MRI images, in acute phase, reveals areas of
increased signal. Brain angiography or digital
subtraction angiography are used to identify the
site of venous occlusions, but they are seldom
indicated because the vessels involved are usual-
ly too small to show abnormalities.
In the group of 200 patients with neuro-Beh-
çet, referred above, 88 performed a CT scan, 101 a
cranial MRI, 12 a spinal MRI and 28 a cerebral
angiography; the attempt to make a radiologic
diagnosis was successful in all BD patients having
an acute attack and in only 40% of BD patients
during the chronic phase17.
In this group of patients 41% of cases had at
least one attack and remission, 28% showed se-
condary progression (slowly evolving and worse-
ning neurological symptoms and signs after at
least one previous attack, or step-wise progres-
sion if there was more than one), 10% had prima-
ry progression (slowly worsening neurological
symptoms and signs over months or years with
no preceding attacks), and 21% had silent neuro-
logical involvement (abnormal findings in neuro-
logical examination in cases who did not have
any neurological complaints).
The following clinical case will highlight seve-
ral clinical and therapeutical difficulties in neuro-
-Behect’s
Clinical case
Male patient, 25 years old, Caucasian, single.
He was admitted to our rheumatology depart-
ment to investigate increasing difficulties in mo-
ving about due to proximal muscle weakness in
the lower limbs, associated with urinary and anal
incontinence as well as sexual impotence. These
symptoms had evolved over six months in a con-
text of Behcet’s disease diagnosed 6 years earlier.
The patient describes recurrent oral aphtosis
since the age of 8. After a few years he began
recurrent episodes of skin lesions diagnosed as
folliculitis and pseudofolliculitis, still present,
affecting trunk and limbs; when he was 18 he had
associated erythema nodosum of the lower limbs.
At age 20 he was diagnosed of posterior uveitis
of the right eye that progressively evolved despite
therapy to complete loss of vision. He was obser-
ved by an ophthalmologist and was prescribed
cyclosporine (2 mg/kg/day) that he maintained
until now, and glucocorticoids (in a dose that he
couldn’t remember) in descending doses, until
the age of 22. He has also taken colchicine (1
mg/day) during flares of oral aphtosis, and tried a
variety of natural medicines. 
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On admission he presented no signs of confu-
sion or emotional disturbance.
The right eye was blind and atrophic. Multiple
oral painful aphtae were present and typical
papulopustular lesions could be found in lower
limbs and dorsal area of the trunk. A systolic mur-
mur could be heard over the mitral focus; he has
normal blood pressure and pulses, and no organ
enlargement was observed in abdominal exami-
nation.
He had an ataxic, asymmetrical and widened
gait. Neurological examination revealed para-
paresis, with a proximal predominance: muscle
power grade 4, in hip flexion and extension, on
the right side and 4- in hip flexion and extension,
on the left. Muscle reflexes were increased in the
lower limbs with a distal clonus and enlarged
reflex area. Babinski`s sign was bilaterally posi-
tive. Primitive reflexes were present, including
palmo-mental, and snout reflexes.
Pin-prick sensation was enhanced over lower
limb, lower sacral roots and discrete areas of the
lower abdomen. No sensitivity level could be de-
fined. There was an abnormal vibration sense in
lower limbs.
Full blood count revealed sideropenic anemia
(Hg: 11,7 gr/dl) with normal platelet and leuko-
cyte counts. Coagulation test were within the nor-
mal range. Liver and muscle enzymes were nor-
mal, as well as kidney function. Serum protein
and immunoelectrophoresis showed no abnor-
mality. 
The E.S.R was raised at 31 mm Hg at the first
hour, and CRP was below 0,5 mg/dl.
Antinuclear antibodies, ANCA and anticardio-
lipin antibodies were negative. 
Serological tests for Hepatitis virus B and C, as
well as HIV 1 and 2 were negative.
Echocardiogram revealed mild mitral insuffi-
ciency, with no other changes.
The cerebrospinal fluid had normal appea-
rance but a high leukocyte count (38/mm3) and
increased protein (81mg/dl). Microbial cultures
were negative. 
An electromyogram of the lower limbs exclu-
ded any signs of neurological or muscular lesion. 
Cranial, dorsal and lumbar MRI failed to show
any significant abnormality (Figs 1 and 2). 
Cerebral SPECT revealed scarcely defined
areas of abnormal perfusion, more pronounced
in the anterior and inferior area of the right
frontal lobe, as well as the right parietal and left
temporal lobes and the basal ganglion region
(Fig. 3).
Magnetic cortical stimulation studies identi-
fied the presence of dorsal medulla dysfunction,
of axonal type, moderately severe. 
Urodynamic investigation concluded for «neu-
rogenic bladder».
Following these investigations the patient was
treated with intravenous boluses of methylpred-
nisolone (1gr/day, in three consecutive days), fol-
lowed by oral prednisolone (1mg/kg/d, in divided
doses) and oral cyclophosphamide (2,5 mg/Kg/
/day).
Two months later the patient described a slight
improvement of sphincter function. Neurological
examination showed no change in comparison to
NEURO-BEHÇET: A CLINICAL EXERCISE
Figure 1 and 2. Cranial, dorsal and lumbar MRI failed to show any significant abnormality.
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the initial status.
Lumbar puncture was repeated and revealed a
normal leukocyte count (4/mm3) with slight
increased protein concentration. 
He was kept on oral cyclophosphamide (150
mg/day equivalent to 2.3 mg/kg/day), methyl-
prednisolone (24 mg/day, 0.5 mg/Kg/day predni-
solone equivalent) and omeprazole (20 mg/od).
He was started on rehabilitation therapy.
At the last observation, with 6 months of thera-
py, the patient described subjective improvement
of muscle power, sphincter control and erection.
Neurological examination still showed no objecti-
ve improvement. 
Discussion
Prof. Hasan Yazici and Prof. Aksel Siva
Question 1: The study and interpretation of this
case was complicated by the negative results of
MRI. How do you interpret this and how can we
overcome these difficulties?
Answer 1: About 10% of all patients with Neuro-
-Behçet’s have negative MRI’s as was the case
with this patient. Unfortunately other laboratory
investigations are of little help. Perhaps the un-
certainty about the precise pathology of the neu-
rologic involvement in Behçet’s is also contribu-
tory to the existence of these MRI negative pa-
tients with neurological disease.  
Question 2: How do you value SPECT in these cir-
cumstances?
Answer 2: SPECT, as is applied to Behçet’s is a very
sensitive tool, as also has been formally demons-
trated21. On the other hand its lack of specificity
limits its routine use as a diagnostic technique.  
Question 3: Some authors suggest that cyclospo-
rine may be, itself, the cause of complications
similar to those of Neuro-Behçet`s17,22. How do
you see this problem? How can we distinguish
both conditions?
Answer 3: The bulk of evidence related to cyclos-
porine associated neurologic toxicity comes from
transplantation data. The usual clinical picture is
that of headache, tremors, cortical blindness and
seizure acitivity. Headache is also common. MRI
shows a leukonecephalopathy with focal lesions.
Tremors and seizure activity, on the other hand
are rather uncommon in Behçet’s. Even though
formal studies are lacking about the frequency of
such toxicity among the Behçet patients, com-
mon wisdom holds that cyclosporine be better
avoided in Behçet’s as in other systemic diseases
with nerologic findings.
Question 4: Is it appropriate and useful to keep
patients under long term cyclosporine, as in this
case?
Answer 4: At our hands the only indication to
keep a patient on long term cyclosporine therapy
is continuing attacks of eye disease. We must
however very closely monitor renal toxicity in
such patients.
Question 5: Do you agree with our therapeutic
options? For how long should we keep these and
other measures?
Answer 5: We would basically do the same in this
patient. Our first choice of cytotoxic agent would
be azathioprine instead of cylophosphamide and
if those cases we used cylcophosphamide we
would add oral MESNA to combat bladder toxi-
city. 
Unfortunately there is no rule of the thumb
one could use to ascertain the duration of treat-
ment. What we usually do is to try to stop the
steroids within a course of months and continue
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Figure 3. Cerebral SPECT. Scarcely defined areas of
abnormal perfusion, more pronounced in the anterior 
and inferior area of the right frontal lobe, as well as the
right parietal and left temporal lobes and the basal gan-
glion region.
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the cytotoxics for at least two years.
Question 6: Are there any further investigations
and treatments we should perform?
Answer 6: Not really.
Question 7: Can you comment on the prognosis?
Answer 7: Unfortunately this patient has a rather
poor prognosis. It is sobering to note that male
patients in this age bracket may have up to 10
times increased mortality when compared to
what we observe in the general population. On
the other hand the positive changes at the end of
6 months of treatment are encouraging indeed.
Question 8: Do you have any other comments?
Answer 8: It is rather interesting that this patient
had a neurogenic bladder without any changes
demonstrable in the MRI of the medulla spinalis.
On the other hand, as was the case with what was
happening in his brain, the patient had objective
evidence of a medulla pathology.
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